Whole-body and adipose tissue-specific mechanisms underlying the metabolic effects of fibroblast growth factor 21 in the Siberian hamster.
Brown adipose tissue
FGF21
Glucose uptake
Lipid uptake
White adipose tissue
β-klotho
Journal
Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
03
09
2019
revised:
19
10
2019
accepted:
30
10
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
2
1
2021
Statut:
ppublish
Résumé
Fibroblast growth factor 21 (FGF21) has been shown to rapidly lower body weight in the Siberian hamster, a preclinical model of adiposity. This induced negative energy balance mediated by FGF21 is associated with both lowered caloric intake and increased energy expenditure. Previous research demonstrated that adipose tissue (AT) is one of the primary sites of FGF21 action and may be responsible for its ability to increase the whole-body metabolic rate. The present study sought to determine the relative importance of white (subcutaneous AT [sWAT] and visceral AT [vWAT]), and brown (interscapular brown AT [iBAT]) in governing FGF21-mediated metabolic improvements using the tissue-specific uptake of glucose and lipids as a proxy for metabolic activity. We used positron emission tomography-computed tomography (PET-CT) imaging in combination with both glucose ( Consistent with previous findings, FGF21 reduced body weight via reduced caloric intake and increased energy expenditure in the Siberian hamster. PET-CT studies demonstrated that FGF21 increased the uptake of glucose in BAT and WAT independently of reduced food intake and body weight as demonstrated by imaging of the pair-fed group. Furthermore, FGF21 increased glucose uptake in the primary adipocytes, confirming that these in vivo effects may be due to a direct action of FGF21 at the level of the adipocytes. Mechanistically, the effects of FGF21 are associated with activation of the ERK signaling pathway and upregulation of GLUT4 protein content in all fat depots. In response to treatment with FGF21, we observed an increase in the markers of lipolysis and lipogenesis in both the subcutaneous and visceral WAT depots. In contrast, FGF21 was only able to directly increase the uptake of lipid into BAT. These data identify brown and white fat depots as primary peripheral sites of action of FGF21 in promoting glucose uptake and also indicate that FGF21 selectively stimulates lipid uptake in brown fat, which may fuel thermogenesis.
Identifiants
pubmed: 31918921
pii: S2212-8778(19)30935-4
doi: 10.1016/j.molmet.2019.10.009
pmc: PMC6889485
pii:
doi:
Substances chimiques
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-54Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M001555/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M021629/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M001555/1
Pays : United Kingdom
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier GmbH.. All rights reserved.
Références
Diabetologia. 2017 Nov;60(11):2274-2284
pubmed: 28770320
J Clin Invest. 1992 Oct;90(4):1386-95
pubmed: 1401073
Cell Metab. 2010 Apr 7;11(4):268-72
pubmed: 20374959
Trends Endocrinol Metab. 2019 Aug;30(8):491-504
pubmed: 31248786
Endocrinology. 2017 Oct 1;158(10):3090-3096
pubmed: 28938451
Physiol Behav. 2018 Jun 1;190:11-20
pubmed: 28694154
Curr Biol. 2015 Nov 16;25(22):2997-3003
pubmed: 26549257
Am J Physiol Regul Integr Comp Physiol. 2010 May;298(5):R1409-16
pubmed: 20200136
J Clin Invest. 2013 Jan;123(1):215-23
pubmed: 23221344
Mol Endocrinol. 2008 Apr;22(4):1006-14
pubmed: 18187602
Mol Metab. 2012 Aug 28;2(1):31-7
pubmed: 24024127
J Lipid Res. 2014 Nov;55(11):2276-86
pubmed: 25193997
Nat Med. 2013 Sep;19(9):1147-52
pubmed: 23933984
Cell Metab. 2016 Mar 8;23(3):427-40
pubmed: 26959184
PLoS One. 2012;7(11):e49977
pubmed: 23209629
Diabetes. 2010 Jan;59(1):61-70
pubmed: 19808894
Sci Rep. 2017 Jun 26;7(1):4238
pubmed: 28652585
Am J Physiol. 1995 Mar;268(3 Pt 2):R744-51
pubmed: 7900918
Trends Endocrinol Metab. 2014 Jun;25(6):303-11
pubmed: 24709036
Cell Metab. 2019 Oct 1;30(4):833-844.e7
pubmed: 31474567
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1105-14
pubmed: 19706786
Am J Physiol Endocrinol Metab. 2016 Mar 15;310(6):E452-60
pubmed: 26732686
J Neuroendocrinol. 2008 Jun;20(6):827-33
pubmed: 18601706
Endocrinology. 2016 Dec;157(12):4754-4769
pubmed: 27690692
Diabetes. 2014 Dec;63(12):4057-63
pubmed: 25008183
Anal Biochem. 1990 Mar;185(2):274-8
pubmed: 2339783
Glia. 2018 Jun;66(6):1176-1184
pubmed: 29411421
Cell Metab. 2013 Sep 3;18(3):333-40
pubmed: 24011069
Endocrinology. 2008 Dec;149(12):6018-27
pubmed: 18687777
Sci Transl Med. 2011 Dec 14;3(113):113ra126
pubmed: 22174314
Cell Metab. 2016 Mar 8;23(3):441-53
pubmed: 26853749
J Physiol. 2015 Feb 1;593(3):701-14
pubmed: 25384777
J Biol Chem. 2007 Sep 14;282(37):26687-95
pubmed: 17623664
J Clin Invest. 2012 Feb;122(2):545-52
pubmed: 22269323
Mol Cell Biol. 2006 May;26(9):3455-67
pubmed: 16611988
Cell Res. 2002 Mar;12(1):9-18
pubmed: 11942415
Cell Metab. 2011 Aug 3;14(2):272-9
pubmed: 21803297
J Neuroendocrinol. 2013 Feb;25(2):180-9
pubmed: 22958332
Front Neurol. 2017 Mar 10;8:79
pubmed: 28344570
J Clin Invest. 2005 Jun;115(6):1627-35
pubmed: 15902306
Diabetes. 2010 Jul;59(7):1817-24
pubmed: 20357365
Cell Metab. 2012 Sep 5;16(3):387-93
pubmed: 22958921
Cell Metab. 2017 Apr 4;25(4):935-944.e4
pubmed: 28380381
Endocrinology. 2015 Jul;156(7):2470-81
pubmed: 25924103
J Biol Chem. 2011 Oct 7;286(40):34533-41
pubmed: 21846717
Endocrinology. 2007 Aug;148(8):4044-55
pubmed: 17463057
Horm Behav. 2014 Jun;66(1):180-5
pubmed: 24909854